Search research articles
Contact Us
Filters
Showing results (41-50 of 53) with videos related to
Page
of 6
Sort By:
Science Translational Medicine
|
September 21, 2022
Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer
Jackson Liang, Ellen Rei Ingalla, Xiaosai Yao, et al.
Cell Chemical Biology
|
May 20, 2026
Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancers
Wei Zhou, Musaddeque Ahmed, Jane Guan, et al.
Cell
|
July 30, 2019
Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility
Jane Guan, Wei Zhou, Marc Hafner, et al.
Cancer Discovery
|
September 21, 2021
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
Kyung W Song, Kyle A Edgar, Emily J Hanan, et al.
Nature Communications
|
August 2, 2025
Epiregulon: Single-cell transcription factor activity inference to predict drug response and drivers of cell states
Tomasz Włodarczyk, Aaron Lun, Diana Wu, et al.
Journal of Medicinal Chemistry
|
June 22, 2026
Utilizing Molecular Dynamics and Mechanistic Pharmacokinetic Studies in the Design of Selective CDK2 Inhibitors
Vishal A Verma, Jessica M Grandner, Brendan T Parr, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 17, 2019
Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma
Sarah M Bronner, Karl A Merrick, Jeremy Murray, et al.
Nature Cancer
|
June 5, 2023
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance
Thijs J Hagenbeek, Jason R Zbieg, Marc Hafner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Dejan Juric, Kyung Song, Radia M Johnson, et al.
Nature Communications
|
June 27, 2026
Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer model
Thijs J Hagenbeek, Jason Zbieg, Russell Smith, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 53) with videos related to
Sort By:
Page
of 6
Science Translational Medicine
|
September 21, 2022
Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer
Jackson Liang, Ellen Rei Ingalla, Xiaosai Yao, et al.
Cell Chemical Biology
|
May 20, 2026
Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancers
Wei Zhou, Musaddeque Ahmed, Jane Guan, et al.
Cell
|
July 30, 2019
Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility
Jane Guan, Wei Zhou, Marc Hafner, et al.
Cancer Discovery
|
September 21, 2021
RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
Kyung W Song, Kyle A Edgar, Emily J Hanan, et al.
Nature Communications
|
August 2, 2025
Epiregulon: Single-cell transcription factor activity inference to predict drug response and drivers of cell states
Tomasz Włodarczyk, Aaron Lun, Diana Wu, et al.
Journal of Medicinal Chemistry
|
June 22, 2026
Utilizing Molecular Dynamics and Mechanistic Pharmacokinetic Studies in the Design of Selective CDK2 Inhibitors
Vishal A Verma, Jessica M Grandner, Brendan T Parr, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 17, 2019
Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma
Sarah M Bronner, Karl A Merrick, Jeremy Murray, et al.
Nature Cancer
|
June 5, 2023
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance
Thijs J Hagenbeek, Jason R Zbieg, Marc Hafner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models
Dejan Juric, Kyung Song, Radia M Johnson, et al.
Nature Communications
|
June 27, 2026
Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer model
Thijs J Hagenbeek, Jason Zbieg, Russell Smith, et al.
Page
of 6